Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

Journal of the National Cancer Institute

Volumn 88, Issue 11, 1996, Pages 734-741

  Kaufmann, Scott H ^a   Peereboom, David ^b,c   Buckwalter, Christopher A ^a   Svingen, Phyllis A ^a   Grochow, Louise B ^b   Donehower, Ross C ^b   Rowinsky, Eric K ^b  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTARABINE; FLUOROURACIL; MELPHALAN; METHOTREXATE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PHASE; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG SYNERGISM; HUMANS; MICROTUBULES; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0029945885     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.11.734     Document Type: Article

References (34)

1. Slichenymer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
2. Feigal EG, Christian M, Cheson B, Grever M, Friedman MA. New chemotherapeutic agents in non-small-cell lung cancer. Semin Oncol 1993;20:185-201.
3. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54:1431-9.
4. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
5. Von Hoff DD, Burris HA 3d. Eckardt J, Rothenberg M, Fields SM, Chen SF. et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994;34:541-5.
6. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995;49:11-9.
7. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
8. Ryan AJ, Squires S, Strutt HL, Johnson RT. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 1991;19:3295-300.
9. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12:530-42.
10. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989;49:6365-8.
11. Drewinko B, Loo TL, Freireich EJ. Combination chemotherapy in vitro. III. BCNU. Cancer Treat Rep 1979;63:373-5.
12. Drewinko B, Green C, Loo TL. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1976;60: 1619-25.
13. Katz EJ, Vick JS, Kling KM, Andrews PA, Howell SB. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 1990;26:724-7.
14. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10.
15. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991;51:1129-36.
16. Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991; 51:5813-6.
17. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res 1992;52:2180-5.
18. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of Taxol, topotecan. and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [see comment citation in Medline], J Natl Cancer Inst 1994;86:1517-24.
19. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994;6:269-79.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
21. Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol 1970;76:77-84.
22. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.
23. Mabry M, Nakagawa T, Nelkin BD, McDowell E, Gesell M, Eggleston JC, et al. v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer. Proc Natl Acad Sci U S A 1988;85:6523-7.
24. Berenbaum MC. What is synergy? [published erratum appears in Pharmacol Rev 1990; 41:422]. Pharmacol Rev 1989;41:93-141.
25. Greco WR, Bravo G, Parsons NC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47: 331-83.
26. Tobey RA. Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse. Cancer Res 1972;32:2720-5.
27. Tsao YP, D'Arpa P, Liu L. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of P34cdc2/cyclin B. Cancer Res 1992;52:1823-9.
28. Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature 1975; 254:245-7.
29. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990;50:6919-24.
30. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattem MR, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20.
31. Mattem MR, Mong SM, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 1987;47: 1793-8.
32. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, Berger NA. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deftcient cell lines. Cancer Commun 1989;1:389-94.
33. Mi LJ, Chiu LN, Mahl E, Boorstein RJ. Toxicity of camptothecin to Chinese hamster cells containing 5-hydroxymethyl-2′-deoxyuridine in their DNA. Mutat Res 1995;336:293-305.
34. Berger SJ, Sudar DC, Berger NA. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 1986;134: 227-32.